These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Elevation of serum soluble tumour necrosis factor receptors in patients with polymyositis and dermatomyositis. Shimizu T; Tomita Y; Son K; Nishinarita S; Sawada S; Horie T Clin Rheumatol; 2000; 19(5):352-9. PubMed ID: 11055823 [TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: prospective analysis of TNF-alpha and 55 kDa TNF receptor in CSF and serum in correlation with clinical and MRI activity. Spuler S; Yousry T; Scheller A; Voltz R; Holler E; Hartmann M; Wick M; Hohlfeld R J Neuroimmunol; 1996 May; 66(1-2):57-64. PubMed ID: 8964914 [TBL] [Abstract][Full Text] [Related]
4. In situ localization of TNFalpha/beta, TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue. Ermert M; Pantazis C; Duncker HR; Grimminger F; Seeger W; Ermert L Cytokine; 2003 May; 22(3-4):89-100. PubMed ID: 12849708 [TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Rieckmann P; Albrecht M; Kitze B; Weber T; Tumani H; Broocks A; Lüer W; Helwig A; Poser S Ann Neurol; 1995 Jan; 37(1):82-8. PubMed ID: 7818262 [TBL] [Abstract][Full Text] [Related]
7. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Spielmann S; Kerner T; Ahlers O; Keh D; Gerlach M; Gerlach H Acta Anaesthesiol Scand; 2001 Mar; 45(3):364-70. PubMed ID: 11207475 [TBL] [Abstract][Full Text] [Related]
8. The soluble 60-kDa tumour necrosis factor receptor: no difference found between patients with relapsing-remitting multiple sclerosis and controls: increasing levels are associated with the recovery from Guillain-Barré syndrome. Patzold T; Sindern E; Ossege-Pohle L; Malin JP J Neurol; 1998 Dec; 245(12):803-8. PubMed ID: 9840353 [TBL] [Abstract][Full Text] [Related]
9. Induction of sTNF-R1 and sTNF-R2 by interferon beta-1b in correlation with clinical and MRI activity. Laske C; Oschmann P; Tofighi J; Kuehne SB; Diehl H; Bregenzer T; Kraus J; Bauer R; Chatzimanolis N; Kern A; Traupe H; Kaps M Acta Neurol Scand; 2001 Feb; 103(2):105-13. PubMed ID: 11227128 [TBL] [Abstract][Full Text] [Related]
10. Relationship between tumour necrosis factor-alpha (TNFalpha) production and a specific multiple sclerosis (MS) associated TNF gene haplotype. Armstrong MA; McDonnell GV; Graham CA; Kirk CW; Droogan AG; Hawkins SA Mult Scler; 1999 Jun; 5(3):165-70. PubMed ID: 10408716 [TBL] [Abstract][Full Text] [Related]
12. Quantification of the mRNA encoding Tumor Necrosis Factor alpha (TNFalpha) and its receptors in human nasal polyps. Rostkowska-Nadolska B; Kapral M; Mazurek U; Fraczek M; Ziolkowski P; Gamian E Adv Med Sci; 2008; 53(2):263-9. PubMed ID: 19095579 [TBL] [Abstract][Full Text] [Related]
13. Serum cytokine levels do not correlate with disease activity and severity assessed by brain MRI in multiple sclerosis. Kraus J; Kuehne BS; Tofighi J; Frielinghaus P; Stolz E; Blaes F; Laske C; Engelhardt B; Traupe H; Kaps M; Oschmann P Acta Neurol Scand; 2002 Apr; 105(4):300-8. PubMed ID: 11939943 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta-1b. Laske C; Oschmann P; Tofighi J; Kühne BS; Diehl H; Bregenzer T; Kraus J; Chatzimanolis N; Bauer R; Traupe H; Kaps M Eur Neurol; 2001; 46(4):210-4. PubMed ID: 11721129 [TBL] [Abstract][Full Text] [Related]
15. Serial analysis of circulating adhesion molecules and TNF receptor in serum from patients with multiple sclerosis: cICAM-1 is an indicator for relapse. Rieckmann P; Martin S; Weichselbraun I; Albrecht M; Kitze B; Weber T; Tumani H; Broocks A; Lüer W; Helwig A Neurology; 1994 Dec; 44(12):2367-72. PubMed ID: 7527508 [TBL] [Abstract][Full Text] [Related]
16. Netrin-1 and multiple sclerosis: a new biomarker for neuroinflammation? Mulero P; Córdova C; Hernández M; Martín R; Gutiérrez B; Muñoz JC; Redondo N; Gallardo I; Téllez N; Nieto ML Eur J Neurol; 2017 Sep; 24(9):1108-1115. PubMed ID: 28677863 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Giovannoni G; Lai M; Thorpe J; Kidd D; Chamoun V; Thompson AJ; Miller DH; Feldmann M; Thompson EJ Neurology; 1997 Jun; 48(6):1557-65. PubMed ID: 9191766 [TBL] [Abstract][Full Text] [Related]
18. Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis. Giovannoni G; Miller DH; Losseff NA; Sailer M; Lewellyn-Smith N; Thompson AJ; Thompson EJ J Neurol; 2001 Jun; 248(6):487-95. PubMed ID: 11499639 [TBL] [Abstract][Full Text] [Related]
19. Role of TNF-alpha and its 55 and 75 kDa receptors in bronchial hyperreactivity. Halász A; Cserháti E; Magyar R; Kovács M; Cseh K Respir Med; 2002 Apr; 96(4):262-7. PubMed ID: 12000006 [TBL] [Abstract][Full Text] [Related]
20. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Khoury SJ; Orav EJ; Guttmann CR; Kikinis R; Jolesz FA; Weiner HL Neurology; 1999 Sep; 53(4):758-64. PubMed ID: 10489037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]